[Evaluation of a combination of colloidal bismuth and pirenzepine in duodenal ulcer in non-responders to anti-H2 receptors].
Manca
A
A
Ferraris
R
R
Ghezzo
L
L
Asnaghi
G
G
Ferro
G F
GF
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001729:Bismuth / Q000008:administration & dosage*; D002927:Cimetidine / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy*; D015738:Famotidine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage*; D010890:Pirenzepine / Q000008:administration & dosage*; D011899:Ranitidine / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D013844:Thiazoles; D010890:Pirenzepine; D015738:Famotidine; D002927:Cimetidine; D011899:Ranitidine; C002791:bismuth tripotassium dicitrate; D001729:Bismuth
Valutazione dell'associazione di bismuto colloidale e pirenzepina nelle ulcere duodenali non responders agli anti-H2 recettori.